Drugs / IBI3032
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07134127 | Aug → Oct 2025 | — | Innovent Biologics Technology Limited (Shanghai R&D Center) | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07170319 | Sep → Dec 2025 overdue | obesity disorder | Innovent Biologics Technology Limited (Shanghai R&D Center) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07120425 | Sep → Nov 2025 overdue | — | Fortvita Biologics (USA)Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07160400 | Sep 2025 → May 2026 overdue | — | Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline innoventbio.com ↗
IBI3032 exhibited potent activation of the human GLP-1R (EC₅₀ = 0.53 nM) with high selectivity and minimal β-a |
| 2025-08-05 | Innovent Biologics (Suzhou) Co. Ltd. | Regulatory Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 innoventbio.com ↗
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company’s novel oral GLP-1R agonist. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Innovent Biologics (Suzhou) Co. Ltd. | 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline innoventbio.com ↗ |
| 2025-08-05 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07134127 ↗ |
| Route | Oral | “Method of administration: oral, fasted administration.” NCT07120425 ↗ |